Atragen

Atragen

Oncology A lipid-based IV formulation of all-trans retinoic acid–ATRA for acute promyelocytic leukemia and other hematologic malignancies, solid tumors. See Promyelocytic leukemia.
References in periodicals archive ?
for its drug Atragen, the manufacturer's stock fell seventy-three percent, and the company expected to reduce its work force of eighty-five in order to preserve cash flow in pursuit of approval for other products.